DCBLD2 Affects the Development of Colorectal Cancer via EMT and Angiogenesis and Modulates 5-FU Drug Resistance

被引:26
|
作者
Xie, Pan [1 ,2 ]
Yuan, Fu-Qiang [1 ,2 ]
Huang, Ma-Sha [1 ,2 ]
Zhang, Wei [1 ,2 ]
Zhou, Hong-Hao [1 ,2 ]
Li, Xi [1 ,2 ]
Liu, Zhao-Qian [1 ,2 ]
机构
[1] Cent South Univ, Hunan Key Lab Pharmacogenet, Dept Clin Pharmacol, Natl Clin Res Ctr Geriatr Disorders,Xiangya Hosp, Changsha, Peoples R China
[2] Cent South Univ, Inst Clin Pharmacol, Changsha, Peoples R China
基金
中国国家自然科学基金;
关键词
colorectal cancer; 5-FU; EMT; drug sensitivity; DCBLD2; EPITHELIAL-MESENCHYMAL TRANSITION; SIGNATURE PREDICTS RESISTANCE; UP-REGULATION; GENE; IDENTIFICATION; CHEMOTHERAPY; STATISTICS; CELLS; CLCP1; EGFR;
D O I
10.3389/fcell.2021.669285
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Background: DCBLD2 is highly expressed in various cancers, including colorectal cancer. DCBLD2 overexpression promotes tumor occurrence, development, and metastasis. However, DCBLD2 sensitivity to chemotherapy drugs and its mechanism on tumor development are unknown. Methods: DCBLD2 expression differences in cancer and normal tissues were obtained from GEO and TCGA databases. DCBLD2 influence on prognosis was also compared, and the database analysis results were verified via the analysis of clinical samples. GDSC database was used to analyze the effect of DCBLD2 expression difference on 5-FU drug sensitivity on tumor cells. CCK-8, clone formation, scratch, Transwell invasion and migration assays were used to assess DCBLD2 effects on the proliferation, metastasis, and 5-FU drug sensitivity on HCT116 and Caco-2 colorectal cancer cells. Angiogenesis and Matrigel plug assays were used to study the effect of DCBLD2 on angiogenesis. Q-RCR and Western Blot were used to analyze DCBLD2 impact on the EMT signaling pathway, and TAP-MS assay with Co-IP verification was used to identify the downstream target proteins binding to DCBLD2. Results: Both database and clinical sample validation results showed that the expression of DCBLD2 in colorectal cancer tissues was significantly higher than that in normal tissues, leading to poor prognosis of patients. GDSC database analysis showed that DCBLD2 overexpression caused tumor cell resistance to 5-FU. The results of in vitro and in vivo experiments showed that the inhibition of DCBLD2 reduced the proliferation, migration and invasion of colorectal cancer cells, inhibited the angiogenesis of endothelial cells, and enhanced the drug sensitivity to 5-FU. The results of q-RCR and Western Blot experiments showed that the inhibition of DCBLD2 can suppress the EMT signal. The results of TAP-MS assay showed that the proteins bound to DCBLD2 were enriched to the Focal adhesion pathway. The results of Co-IP assay show that DCBLD2 can combine with ITGB1, the key factor of Focal adhesion pathway. Conclusion: DCBLD2 may affect the development of colorectal cancer by regulating cell proliferation and motility, and modulate 5-FU resistance. Down-regulation of DCBLD2 can inhibit EMT signal and angiogenesis. DCBLD2 can combine with ITGB1, the key signal factor of the Focal adhesion pathway.
引用
收藏
页数:14
相关论文
共 50 条
  • [31] Therapeutic drug monitoring of 5-fluorouracil (5-FU) in the treatment of patients with colorectal cancer (CRC)
    Goel, Gaurav
    Sehgal, Rajesh
    Meisner, Dennis James
    Sun, Min
    Pasricha, Gurleen
    Chu, Edward
    Lee, James J.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [32] Nanoparticle delivery of si-Notch1 modulates metabolic reprogramming to affect 5-FU resistance and cell pyroptosis in colorectal cancer
    Li, Dan-dan
    Jin, Jia-cheng
    Liu, Xuan-wen
    Liu, Shu-yang
    Ji, Fu-jian
    Liu, Tong
    CANCER NANOTECHNOLOGY, 2024, 15 (01)
  • [34] Targeting REV7 effectively reverses 5-FU and oxaliplatin resistance in colorectal cancer
    Sun, Xianjun
    Hou, Wenhou
    Liu, Xin
    Chai, Jie
    Guo, Hongliang
    Yu, Jinming
    CANCER CELL INTERNATIONAL, 2020, 20 (01)
  • [35] tsRNA-GlyGCC promotes colorectal cancer progression and 5-FU resistance by regulating SPIB
    Xu, Rong
    Du, Ashuai
    Deng, Xinpei
    Du, Wei
    Zhang, Kaiying
    Li, Jianbo
    Lu, Yingxue
    Wei, Xiaoli
    Yang, Qinglong
    Tang, Hailin
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2024, 43 (01)
  • [36] Targeting REV7 effectively reverses 5-FU and oxaliplatin resistance in colorectal cancer
    Xianjun Sun
    Wenhou Hou
    Xin Liu
    Jie Chai
    Hongliang Guo
    Jinming Yu
    Cancer Cell International, 20
  • [37] 5-FU resistance in colorectal cancer cells based on lncRNA CUDR mediated autophagy pathway
    Chen, Bi
    CANCER SCIENCE, 2022, 113 : 889 - 889
  • [38] CTCF promotes colorectal cancer cell proliferation and chemotherapy resistance to 5-FU via the P53-Hedgehog axis
    Lai, Qiuhua
    Li, Qingyuan
    He, Chengcheng
    Fang, Yuxin
    Lin, Simin
    Cai, Jianqun
    Ding, Jian
    Zhong, Qian
    Zhang, Yue
    Wu, Changjie
    Wang, Xinke
    He, Juan
    Liu, Yongfeng
    Yan, Qun
    Li, Aimin
    Liu, Side
    AGING-US, 2020, 12 (16): : 16270 - 16293
  • [39] Kaempferol Can Reverse the 5-Fu Resistance of Colorectal Cancer Cells by Inhibiting PKM2-Mediated Glycolysis
    Wu, Haili
    Du, Jin'e
    Li, Chenglu
    Li, Hanqing
    Guo, Huiqin
    Li, Zhuoyu
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (07)